Skip to main content
Premium Trial:

Request an Annual Quote

HTG Molecular Gets CE Mark for Lung Cancer CDx

NEW YORK (GenomeWeb) – HTG Molecular Diagnostics announced yesterday that it has secured CE marking for its HTG EdgeSeq ALKPlus assay EU, clearing the test for sale in the European Union.

The in vitro diagnostic runs on HTG's EdgeSeq next-generation sequencing system and is designed to measure and analyze mRNA ALK gene rearrangements in lung tumor specimens from patients previously diagnosed with non-small cell lung cancer. It can be used to identify patients suitable for treatment with ALK-targeted therapeutics such as Pfizer's Xalkori (crizotinib).

"We are pleased to add the HTG EdgeSeq ALKPlus assay EU to our diagnostic assay menu in Europe," HTG President and CEO T.J. Johnson said in a statement. "We plan to offer this assay to selected European early adopters as we seek additional regulatory approvals elsewhere."

In January, HTG announced that it had submitted the third of four expected modules for the assay's premarket approval application to the US Food and Drug Administration. The fourth module is expected to be completed this year.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.